You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Imatinib mesylate

Showing 1 - 25 of 997
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastrointestinal Stromal Tumor of Rectum Trial in Fuzhou (Imatinib Mesylate, Local resection)

Not yet recruiting
  • Gastrointestinal Stromal Tumor of Rectum
  • Imatinib Mesylate
  • Local resection
  • Fuzhou, Fujian, China
    Weizhong Jiang
Jul 23, 2023

CML Trial in Tempe (Imatinib Mesylate, IkT-001Pro)

Recruiting
  • CML
  • Tempe, Arizona
    Celerion
Nov 21, 2022

Gastrointestinal Stromal Tumor (GIST) Trial in New York (drug, other, procedure)

Active, not recruiting
  • Gastrointestinal Stromal Tumor (GIST)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 28, 2022

Melanoma Trial in Shinjuku (Pembrolizumab and Imatinib mesylate)

Recruiting
  • Melanoma
  • Pembrolizumab and Imatinib mesylate
  • Shinjuku, Tokyo, Japan
    Keio University Hospital
Mar 29, 2022

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

Breast Cancer Trial in United States (gemcitabine HCl, imatinib mesylate)

Terminated
Has Results
  • Breast Cancer
  • gemcitabine hydrochloride
  • imatinib mesylate
  • Chicago, Illinois
  • +8 more
Aug 12, 2022

Melanoma Stage III, Melanoma Stage IV Trial in San Francisco (Binimetinib, Imatinib)

Recruiting
  • Melanoma Stage III
  • Melanoma Stage IV
  • San Francisco, California
    University of California, San Francisco
Dec 6, 2022

Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

Completed
  • Gastrointestinal Stromal Tumors (GISTs)
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center
Dec 30, 2022

Gastrointestinal Stromal Tumors Trial (Imatinib Mesylate)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Imatinib Mesylate
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Dec 22, 2022

Advanced Melanoma Trial in Beijing (JS001+Imatinib mesylate)

Recruiting
  • Advanced Melanoma
  • JS001+Imatinib mesylate
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Mar 2, 2022

Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))

Completed
Has Results
  • Chronic Myelomonocytic Leukemia
  • +4 more
  • Imatinib Mesylate (Gleevec)
  • Houston, Texas
    UT MD Anderson Cancer Center
Dec 7, 2021

Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • (no location specified)
Jun 7, 2022

Gastrointestinal Stromal Tumor, Malignant Trial in Changsha (Entacapone, Imatinib Mesylate)

Active, not recruiting
  • Gastrointestinal Stromal Tumor, Malignant
  • Changsha, Hunan, China
    Bin Li, MD
Nov 24, 2021

Myeloid Leukemia, Chronic Trial in France (Glivec)

Terminated
Has Results
  • Myeloid Leukemia, Chronic
  • Bordeaux, France
  • +6 more
Nov 5, 2021

Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant Trial in Hangzhou (Imatinib)

Recruiting
  • Progression-free Survival
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 9, 2021

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

Tuberculosis Trial in Atlanta (Imatinib, Isoniazid, Rifabutin)

Recruiting
  • Tuberculosis
  • Atlanta, Georgia
    Emory University DAIDS TB Non-Network CRS
Jan 20, 2022

Chronic Myelogenous Leukemia Trial in Beirut (Nilotinib)

Recruiting
  • Chronic Myelogenous Leukemia
  • Beirut, Lebanon
    American University of Beirut Medical Center
Feb 14, 2022

Leukemia Trial in Portland (cyclophosphamide, cytarabine, dexamethasone)

Terminated
Has Results
  • Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 13, 2022

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial

Recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
  • Houston, Texas
  • +3 more
Jan 25, 2022

Gastrointestinal Stromal Tumors Trial in Seoul (Rivoceranib Mesylate, Paclitaxel)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Rivoceranib Mesylate, Paclitaxel
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Jun 7, 2023

Leukemia, Myeloid, Chronic-Phase Trial in Bordeaux (Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet,

Terminated
Has Results
  • Leukemia, Myeloid, Chronic-Phase
  • Imatinib Mesylate 600 MG Oral Tablet
  • +2 more
  • Bordeaux, Aquitaine, France
    Institut Bergonié
Dec 30, 2020

Mesothelioma, Malignant Trial in Rozzano (Gemcitabine, Imatinib mesylate)

Completed
  • Mesothelioma, Malignant
  • Rozzano, MI, Italy
    Istituto Clinico Humanitas
Jan 20, 2021

Philadelphia Chromosome Positive CML Trial in Worldwide (imatinib mesylate)

Completed
Has Results
  • Philadelphia Chromosome Positive CML
  • imatinib mesylate
  • Chicago, Illinois
  • +9 more
Jun 3, 2021